Matthew Perry Investigation: Can Ketamine Kill Someone?

Updated Aug 17, 2024 | 12:00 PM IST

SummaryNew evidence has come up in the investigation of Matthew Perry, 'Friends' Chandler Bing's death on October 28. This evidence points to an overdose of ketamine. What is ketamine and how does it affect you? Read now.
Matthew Perry Investigation Can Ketamine Kill Someone

Credits: IMDb

“I'm not great at the advice. Can I interest you in a sarcastic comment?”

Friends Actor Matthew Perry

This is what ‘Friends’ actor Matthew Perry’s character Chandler Bing was known for. He was known for being funny. However, he had his own struggles in his personal life and those struggles were acute depression. He was treating it with ketamine infusion therapy which is legal in the US and the UK.

What is Ketamine infusion therapy?

Ketamine is an anaesthetic used to treat depression, anxiety and pain under supervised and controlled medical settings. However, it does have its side effects, which can lead to distortion of sight, sound and time. It can also produce calming and relaxing effects.

Ketamine increases a person’s heart rate and blood pressure. If overdosed, it can leave users confused and agitated and can cause them to hurt themselves without even realising it. It can also lead to liver damage and bladder problems.

However, when used in moderation and under the supervision of medical doctors, it can treat depression where traditional antidepressants have failed.

Prof Rupert McShane, a University of Oxford psychiatrist who runs an NHS ketamine treatment clinic told BBC that ketamine “probably turns off the area of the brain that is involved in disappointment.”

Can Ketamine Infusion Therapy Kill Someone?

In simple terms, it cannot, be if the dosage is given in a controlled setting and as prescribed. Ketamine infusion therapy uses drugs in small doses than those used for anaesthesia. It acts faster than traditional anti-depressants, but the effects also wear off way quickly. Which is why it is important to monitor patients’ mental state for relapsing back into depression and discouraging them from overdosing on it.

There are ways of giving people ketamine. One of the ways is through “infusing”, which means to use an IV drip. However, injections, nasal sprays and capsules are also methods used to give people ketamine.

Since the dosage of ketamine used in the infusion treatment is small, it being the reason of actor Perry’s death was ruled out. The medical examiner also noted that Perry’s last ketamine infusion therapy session happened more than a week before his death, which means by the time he had died, it must have worn off.

So, What Happened To Perry?

Though Perry’s last session was more than a week before, his post-mortem showed that his blood contained a high concentration of ketamine. He had died of the “acute effects” of ketamine.

If it was not his session, then how did he get ketamine?

Prosecutors alleged that his assistant gave him at least 27 shots of ketamine in four days before his death, reported BBC.

Perry has been open about his personal struggles and this is what the doctors and dealers used against him. Martin Estrada, the US attorney for California’s Central District told the BBC that people took advantage of his condition. They charged him 165 times more than what vials of ketamine cost.

Names that have come up include Dr Salvador Plasencia, drug dealers “Ketamine Queen” aka Jasveen Sangha and Eric Fleming, and Perry’s live-in assistant Kenneth Iwamasa.

Who Are These Names And What Did They Do?

Ketamine Queen or Sangha supplied drugs that led to Perry’s death. Her home was a “drug-selling emporium,” said Estrada. More than 80 vials of ketamine, and thousands of pills including methamphetamine, cocaine and Xanax were allegedly found in her house known as the “Sangha Stash House.”

Sangha is known to deal with high-end celebs and was a “major source of supply for ketamine to others as well as Perry,” said Estrada.

Dr Plasencia called Perry a “moron” while charging him $2,000 for vials that cost only $12. He sold Perry 20 vials of ketamine between September and October 2023, costing $55,000.

He was the one who taught Iwamasa, who had no medical knowledge to inject the drug. This is after he knew that “Perry’s ketamine addiction was spiralling out of control,” as per what the investigators told the BBC.

Another dealer Fleming was told by Sangha to “delete all our messages.” While Fleming pleaded guilty to conspiring to distribute drugs unlawfully, he also allegedly messaged Sangha: “Please call...Got more info and want to bounce ideas off you. I’m 90% sure everyone is protected. I never dealt with [Perry] only his assistant. So the assistant was the enabler.”

The court documents also revealed that he asked Sangha on whether the ketamine stays in your system or “is it immediately flushed out.”

Dr Pepper, Bots, Cans

The people who allegedly exploited Perry used coded language for ketamine and called it “Dr Pepper”, “bots”, or “cans.”

Selling overpriced drugs, taking advantage of Perry’s mental condition and falsifying medical records to make the drugs given to him look legitimate by Dr Plasencia is what took Perry’s life.

Iwamasa is said to have administered more than 20 shots of ketamine and three on the day Perry died. Whereas ketamine is only administered by a physician. Authorities also found that weeks before Perry’s death, Dr Plasencia allegedly bought 10 vials of ketamine and intended to sell to Perry.

He also injected Perry with a large dose, two days later. This caused him to “freeze up” and spiked his blood pressure.

When I Die, I Want Helping Others To Be The First Thing That’s Mentioned

Perry had always been open about his drug addictions, struggles with alcohol and his depression. He said that his openness would help others who are also struggling and wanted to be remembered by his quote which also is on the homepage of the Mattew Perry Foundation that helps others struggling with the disease of addiction: “When I die, I want helping others to be the first thing that’s mentioned.”

Five arrests have been made in the case so far.

End of Article

Melatonin Or Insomnia? Scientists Question 90% Higher Heart Failure Risk Linked To Long-Term Use Of The Supplement

Updated Aug 31, 2026 | 01:00 AM IST

SummaryA recent study has observed that those who used melatonin supplement for 12 months or more are at a significantly higher risk of heart failure.
Long-Time Melatonin Use Linked To 90% Higher Heart Failure Risk: Why You Need To Be Careful With The Supplement?

Credit: AI

Melatonin is often opted to treat a bad night's sleep. But new research is raising an important question about what happens when the sleep supplement becomes a long-term habit.

A large preliminary study found that people with chronic insomnia who used melatonin for at least 12 months had a roughly 90% higher risk of developing heart failure over five years compared with similar people who did not use it.

The findings were presented at the American Heart Association's Scientific Sessions and are based on health-record data. Researchers have stressed that the study does not conclusively prove that melatonin causes heart failure.

About The Study

The researchers observed adults with insomnia and compared those who used melatonin for 12 months or more with those who didn't.

Over a period of five years, 4.6% of long-term melatonin users developed heart failure, compared to 2.7% of non-users. That translated into approximately a 90% higher risk.

Researchers found a similar association when they used a stricter definition of long-term use, looking at people who had filled at least two melatonin prescriptions at least 90 days apart. In that analysis, the risk was 82% higher.

So, it does not mean that 90 out of 100 people taking melatonin will develop heart failure. It means the relative risk was about 90% higher in the long-term melatonin group than in the comparison group.

Also read: French Court Links Flight Attendant’s Breast Cancer To Workplace Radiation; How Does Flying Increase Cancer Risk?

How Does Melatonin Help Sleep Better?

Melatonin is a hormone naturally produced by the body, mainly in response to darkness. It helps regulate the sleep-wake cycle, essentially telling the body that night time has arrived. Melatonin supplements are therefore used to help with sleep problems.

But chronic insomnia itself is not harmless. Poor sleep can be associated with high blood pressure, obesity, diabetes, and cardiovascular disease. And that creates a major problem in interpreting this study.

Also read: How To Read Your Blood Test Results: A Simple Guide To What Your Numbers Mean

Melatonin Or Insomnia: What Is Causing Heart Risk?

People taking melatonin long term may have more severe or persistent insomnia than people who do not take it. That underlying sleep disorder could itself contribute to cardiovascular problems.

There may also be other differences between the two groups that a medical-record study cannot completely account for. This is why the researchers have described the findings as preliminary and say more research is needed to understand whether melatonin itself has a harmful cardiovascular effect.

Talking about heart failure, it simply does not mean that the heart suddenly stops working. It means the heart has become unable to pump blood efficiently enough to meet the body's needs. People may develop symptoms like:

  • Breathlessness, particularly when lying down or exercising
  • Persistent tiredness
  • Swelling of the legs, ankles or feet
  • Rapid weight gain from fluid retention
  • A persistent cough or congestion
  • Reduced ability to exercise

Does This Mean You Should Stop Taking Melatonin?

The research is merely observational, so it cannot establish cause and effect. It also does not show that short-term melatonin use causes heart failure.

The American Heart Association described the findings as raising “new questions about the safety of taking melatonin for extended periods.”

If someone has been taking melatonin every night for months or years, particularly because of persistent insomnia, it may be worth discussing the underlying sleep problem with a doctor rather than simply continuing the supplement indefinitely.

End of Article

Lowering Cholesterol May Protect Your Brain As Study Links Statins To 15% Lower Dementia Risk

Updated Aug 30, 2026 | 11:00 PM IST

SummaryA recent study observed thousands of people with type 2 diabetes who started taking statins earlier and found that they were at a significantly lower risk of dementia.
Lowering Cholesterol May Protect Your Brain As Study Links Statins To 15% Lower Dementia Risk

Credit: AI

Statins have long had the job of lowering LDL cholesterol and protecting the heart. But new a study has emerged stating that these medicines may have another significant benefit for the brain.

A 15-year Danish study involving more than 132,000 people with type 2 diabetes found that those who started taking statins earlier had a 15% lower risk of developing dementia compared with those who started treatment later. Even later, statin use was associated with a 10% lower risk.

The researchers suggest that the timing of treatment is key as prolonged exposure to high cholesterol and other cardiovascular risk factors could contribute to damage that accumulate over many years.

The findings, presented at the European Society of Cardiology Congress and published in The Lancet Regional Health – Europe, come as researchers are constantly exploring the connection between cholesterol, blood vessels, and brain health.

Connection Between Cholesterol And Brain

The brain is an enormous delivery network in which billions of cells depend on a constant supply of oxygen and nutrients delivered through tiny blood vessels.

High levels of LDL cholesterol can contribute to atherosclerosis, where fatty deposits build up inside arteries. Over time, this can damage blood vessels and restrict blood flow.

Damage to the brain's blood vessels can contribute to vascular cognitive impairment and vascular dementia, while strokes can also increase the risk of subsequent cognitive decline.

Also read: Hormone Replacement Therapy May Lower Dementia Risk In Women, Shows Study

Statins Were Not Proven To Prevent Dementia

This study merely observed the correlation between statins and dementia risk, meaning it did not establish a definite cause-and-effect relationship. People who start statins earlier may also differ from those who start later in other ways, including their overall management of diabetes and cardiovascular risk.

The researchers therefore say more work is needed to determine whether statins have a direct protective effect on the brain.

Also read: Bruce Willis’ Daughter Rumer Undergoes ‘Terrifying’ Genetic Tests Amid Dad’s Dementia Diagnosis

Does Lower Cholesterol Mean Better Brain Health?

It is important to note the difference between treating unhealthy LDL cholesterol levels and assuming that everyone should aggressively lower cholesterol to prevent dementia. Statins remain as the medication to reduce cardiovascular risk.

Their potential brain benefits are an additional area of research. So, people must not blindly start popping statins to lower the risk of neurodegenerative diseases like dementia.

There is another reassuring point for people already taking statins. The concerns that these medicines may result in the increase of dementia risk have not been supported by the strongest available evidence.

A large review of randomised trials earlier this year found that most reported statin side effects were no more common than with placebo, including reported memory problems.

The most interesting takeaway may not be that “statins prevent dementia.” The evidence isn't strong enough to make that claim yet. It is that heart health and brain health are deeply intertwined.

Managing cholesterol, blood pressure, diabetes and other cardiovascular risk factors, along with regular physical activity and a healthy diet, may help protect the blood vessels that keep the brain functioning.

End of Article

Cipla's Drug License Cancelled Over Reactin Plus, Then Restored: Why Did Bombay HC Pull Up Maharashtra FDA?

Updated Aug 30, 2026 | 09:05 PM IST

SummaryBombay High Court recently slammed Maharashtra FDA for hasty conduct after the drug regulator cancelled Cipla facility's license due to certain violations associated with Reactin Plus.
Cipla's Drug License Cancelled Over Reactin Plus, Then Restored: Why Did Bombay HC Pull Up Maharashtra FDA?

Credit: AI

The Maharashtra Food and Drug Administration (FDA) has recently sparked headlines for bringing several known brands under its tight scrutiny. Cipla was one of them after the drug regulator cancelled one of its facility’s licenses over alleged violations associated with Reactin Plus tablets.

Soon after that, the Bombay High Court questioned the manner in which the action was taken, prompting the Maharashtra Food and Drug Administration (FDA) to withdraw its cancellation order.

The dispute has now become more about how far a regulator can go while enforcing drug safety rules, and whether due process was followed before cancelling the license.

Why Did Maharashtra FDA Cancel Cipla Facility’s License?

Maharashtra FDA recently conducted an inspection of Cipla Pharma & Life Sciences’ carrying and forwarding facility at Wadki in Pune.

During an inspection in June, FDA officials found that the packaging of Reactin Plus, a Schedule H prescription medicine, described it as an “analgesic and antipyretic”. The FDA said this amounted to unauthorised advertising of a prescription drug and violated provisions of the Drugs and Cosmetics Act and Rules.

The regulator seized Reactin Plus stock worth around Rs 11.19 lakh and instructed that the product be recalled.

But the FDA said the recall directions were not fully complied with. A subsequent inspection also found discrepancies between physical stock, computerised records and purchase and sales data.

Medicines were reportedly found stored directly on the floor, with inadequate proper storage arrangements. Deficiencies were also identified in the handling of expired medicines.

Based on these findings, the FDA cancelled the drug-sale licenses of the facility with effect from August 27.

Maharashtra FDA Commissioner Tukaram Mundhe said, “The Food and Drug Administration will not show any leniency regarding the safety of medicines and the health of citizens.”

He added, “Any entity within the pharmaceutical manufacturing and distribution system found violating regulations will face stringent legal action.”

Also read: FSSAI Proposes Red Front-Of-Pack Warning Labels On Junk Food: How Will This Benefit Consumers’ Health?

Why Did The Bombay High Court Step In?

Cipla challenged FDA's action before the Bombay High Court. On August 30, the court criticised the regulator's approach, describing it as “high-handed” and saying the FDA had gone “overboard”. The court also questioned whether the principles of natural justice had been followed.

During the hearing, the court asked, “Do you feel you are a Lord and you can do anything?”

The court's concern was not necessarily that the FDA should not regulate Cipla. Instead, it questioned the manner and procedure through which the license was cancelled.

Following the court's intervention, the Maharashtra FDA withdrew the cancellation order and said it would issue a fresh show-cause notice before passing an order.

So, the license has been restored for now, but that does not mean the underlying regulatory concerns have disappeared.

Also read: Everest Hing Sale Prohibited By FSSAI; 3 Other Masalas Flagged For Violations

What Does Cipla Say?

Cipla has maintained that the matter is under judicial consideration and therefore declined to comment in detail. The company said the FDA order relates to the operations of a C&F warehouse, rather than allegations concerning the medicine's safety or effectiveness.

According to mint, Cipla said, “Cipla has been a trusted healthcare organization for nine decades and continues to uphold the highest standards of quality, regulatory compliance, and patient safety.”

The company also clarified that the FDA order “does not allege any concerns relating to the safety, quality or efficacy of its products”.

Reactin Plus Is Safe

The FDA action focuses on violations related to labelling, recall compliance, storage, inventory records and distribution practices.

It did not establish that Reactin Plus was unsafe, ineffective, or contaminated. Cipla has specifically said the order did not concern the product's safety, quality, or efficacy.

End of Article